ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATHENA; ATHENA-COMBO; ATHENA-MONO
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 04 Jun 2024 Final safety results of this study presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 09 Dec 2022 This trial has been completed in Finland according to European Clinical Trials Database record.
- 13 Sep 2022 Results (data cutoff As of March 23, 2022 ) of subgroup analysis evaluating if all patients benefited from rucaparib 1L maintenance treatment, including those with more favourable prognostic factors at baseline, presented at the 47th European Society for Medical Oncology Congress